Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)

NCT02321878 · Completed

Last updated 2026-05-28

This clinical trial observes the safety of Victoza® (liraglutide) in adults with type 2 diabetes by tracking the number of side effects that occur during real-world use.

Status Completed The study has finished.

Type Observational

Participants 1,092 people

Who can join all sexes

Timeline Started 2014-12 · est. completion 2017-06

Where 5 sites · Japan

What this study is testing ClinicalTrials.gov NCT02321878 ↗

Description as written by the study sponsor.

This trial is conducted in Asia. The aim of this trial is to evaluate safety and effectiveness of Victoza® in patients with type 2 diabetes mellitus (T2DM) in combination with antidiabetes agents other than sulfonylurea under post-marketing normal clinical practice conditions.

Treatments tested

liraglutide Drug

Liraglutide (Victoza®) will be prescribed by the physician under normal clinical practice conditions. No treatment given.

Main thing measured	Number of AEs (adverse events)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02321878 ↗